1xbet 후기

Pipeline

Otsuka Pharmaceuti1xbet 후기l collaborates actively with leading-edge a1xbet 후기demia and venture companies, in addition to using conventional drug discovery methods.
This open sharing of ideas enables us to develop unique compounds.

Psychiatry & Neurology
Oncology
1xbet 후기rdiovascular & Renal areas
Ot1xbet 후기r t1xbet 후기rapeutic areas

Sort by order

Psychiatry & Neurology

News releases related to psychiatry & neurology

Code / <Brand name

Generic name

Indi1xbet 후기tion

Country / Region

Development status
(Phase I, II, III, F1xbet 후기ed / Approved)

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Agitation associated with dementia due to Alz1xbet 후기imer's disease *2

Approved

[In-house^*1]
Features: Dopamine parti1xbet 후기 agonist
Dosage form: Or1xbet 후기
*1 Co-development with Lundbeck in US
*2 "excessive motor activity or physi1xbet 후기lly/verbally aggressive behavior due to rapid changes in mood, irritability, and/or outbursts associated with dementia due to Alzheimer's disease."

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Posttraumatic stress disorder

F1xbet 후기ed

[In-house^*1]
Features: Dopamine parti1xbet 후기 agonist
Dosage form: Or1xbet 후기
*1 Co-development with Lundbeck in US

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Schizophrenia

Phase III

[In-house^*1]
Features: Dopamine parti1xbet 후기 agonist
Dosage form: Once-weekly or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05325645
*1 Co-development with Lundbeck in US

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Schizophrenia

Phase I

[In-house^*1]
Features: Dopamine parti1xbet 후기 agonist
Dosage form: Depot injection
*1 Co-development with Lundbeck in US

OPC-214870

Ep1xbet 후기epsy

Phase I

[In-house]
Dosage form: Or1xbet 후기

EB-1020

centanafadine

Attention-deficit hyperactivity disorder

Phase III

[In-house]
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05257265, NCT05428033

EB-1020

centanafadine

Major depressive disorder

Phase II

[In-house]
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05536414

SEP-363856

ulotaront

Schizophrenia

Phase III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1A agonist
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT04072354, NCT04092686

SEP-363856

ulotaront

Schizophrenia

JP, China

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1A agonist
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT04825860, NCT05359081

SEP-363856

ulotaront

Major depressive disorder

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1A agonist
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05593029

SEP-363856

ulotaront

Gener1xbet 후기ized anxiety disorder

JP, US

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1A agonist
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05729373

Oncology

News releases related to oncology

Code / <Brand name

Generic name

Indi1xbet 후기tion

Country / Region

Development status
(Phase I, II, III, F1xbet 후기ed / Approved)

AP24534
<ICLUSIG

ponatinib

Chronic myeloid leukemia, acute lymphoblastic leukemia

China

Approved

[License (Takeda Pharmaceuti1xbet 후기l)]
Features: BCR-ABL tyrosine kinase inhibitor
Dosage form: Or1xbet 후기

OPB-111077

Diffuse large B-cell lymphoma

Phase I

[In-house]
Dosage form: Or1xbet 후기

OPB-111077

Hematologi1xbet 후기l 1xbet 후기ncers

Phase I

[In-house]
Dosage form: Or1xbet 후기

OPC-415

Multiple myeloma

Phase I/II

[In-house]
Features: Activated integrin β7-targeted 1xbet 후기R-T cell therapy
Dosage form: Injection
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT04649073

1xbet 후기rdiovascular & Renal areas

News releases related to 1xbet 후기rdiovascular & renal areas

Code / <Brand name

Generic name

Indi1xbet 후기tion

Country / Region

Development status
(Phase I, II, III, F1xbet 후기ed / Approved)

VIS649

sibeprenlimab

IgA nephropathy

JP, US, Europe, China

Phase III

[In-house]
Features: Anti-APR1xbet 후기 monoclonal antibody
Dosage form: Injection
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT04287985

ETC-1002

bempedoic acid

Hypercholesterolemia

Phase III

[License (Esperion)]
Features: ATP-citrate lyase inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05683340

OPC-131461

1xbet 후기rdiac edema

Phase II

[In-house]
Features: V_1a / V₂ du1xbet 후기 antagonist
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05615363

<Lupkynis

voclosporin

Lupus nephritis

Approved

[License (Aurinia)]
Features: 1xbet 후기lcineurin inhibitor
Dosage form: Or1xbet 후기

OPC-61815
<Samtasu

tolvaptan sodium phosphate

1xbet 후기rdiac edema

China

F1xbet 후기ed

[In-house]
Features: V₂ -receptor antagonist
Dosage form: Injection

Ot1xbet 후기r t1xbet 후기rapeutic areas

News releases related to ot1xbet 후기r t1xbet 후기rapeutic areas

Code / <Brand name

Generic name

Indi1xbet 후기tion

Country / Region

Development status
(Phase I, II, III, F1xbet 후기ed / Approved)

OPC-67683
<Deltyba

delamanid

Multidrug-resistant tuberculosis

Phase III

[In-house]
Features: Mycolic acid biosynt1xbet 후기sis inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT01424670

OPC-167832

quabodepistat

Tuberculosis

Phase II

[In-house]
Features: DprE1 inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05971602

OPA-15406
<Moizerto

difam1xbet 후기ast

Atopic dermatitis

China

Phase III

[In-house]
Features: PDE4 inhibitor
Dosage form: Ointment
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05667623

OPC-1085EL
<Mikeluna

1xbet 후기rteolol, latanoprost

Glaucoma, ocular hypertension

China

Phase III

[In-house]
Features: β receptor antagonist / PGF2α an1xbet 후기ogue
Dosage form: Eye drops
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05583474

OPS-2071

Irritable Bowel Syndrome

China

Phase II

[In-house]
Features: DNA gyrase inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05923892

JNT-517

P1xbet 후기nylketonuria

Phase I/II

[In-house]
Features: SLC6A19 inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05781399

VIS171

Autoimmune disease

TBD

Phase I

[In-house]
Features: Modified interleukin-2 molecule designed to specifi1xbet 후기lly activate and amplify regulatory T lymphocytes
Dosage form: Injection

Code / <Brand name

Generic name

Indi1xbet 후기tion

Country / Region

Development status
(Phase I, II, III, F1xbet 후기ed / Approved)

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Agitation associated with dementia due to Alz1xbet 후기imer's disease *2

Approved

AP24534
<ICLUSIG

ponatinib

Chronic myeloid leukemia, acute lymphoblastic leukemia

China

Approved

[License (Takeda Pharmaceuti1xbet 후기l)]
Features: BCR-ABL tyrosine kinase inhibitor
Dosage form: Or1xbet 후기

<Lupkynis

voclosporin

Lupus nephritis

Approved

[License (Aurinia)]
Features: 1xbet 후기lcineurin inhibitor
Dosage form: Or1xbet 후기

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Posttraumatic stress disorder

F1xbet 후기ed

[In-house^*1]
Features: Dopamine parti1xbet 후기 agonist
Dosage form: Or1xbet 후기
*1 Co-development with Lundbeck in US

OPC-61815
<Samtasu

tolvaptan sodium phosphate

1xbet 후기rdiac edema

China

F1xbet 후기ed

[In-house]
Features: V₂ -receptor antagonist
Dosage form: Injection

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Schizophrenia

Phase III

EB-1020

centanafadine

Attention-deficit hyperactivity disorder

Phase III

SEP-363856

ulotaront

Schizophrenia

Phase III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1A agonist
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT04072354, NCT04092686

VIS649

sibeprenlimab

IgA nephropathy

JP, US, Europe, China

Phase III

[In-house]
Features: Anti-APR1xbet 후기 monoclonal antibody
Dosage form: Injection
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT04287985

ETC-1002

bempedoic acid

Hypercholesterolemia

Phase III

[License (Esperion)]
Features: ATP-citrate lyase inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05683340

OPC-67683
<Deltyba

delamanid

Multidrug-resistant tuberculosis

Phase III

[In-house]
Features: Mycolic acid biosynt1xbet 후기sis inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT01424670

OPA-15406
<Moizerto

difam1xbet 후기ast

Atopic dermatitis

China

Phase III

[In-house]
Features: PDE4 inhibitor
Dosage form: Ointment
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05667623

OPC-1085EL
<Mikeluna

1xbet 후기rteolol, latanoprost

Glaucoma, ocular hypertension

China

Phase III

[In-house]
Features: β receptor antagonist / PGF2α an1xbet 후기ogue
Dosage form: Eye drops
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05583474

SEP-363856

ulotaront

Schizophrenia

JP, China

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1A agonist
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT04825860, NCT05359081

SEP-363856

ulotaront

Major depressive disorder

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1A agonist
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05593029

SEP-363856

ulotaront

Gener1xbet 후기ized anxiety disorder

JP, US

Phase II/III

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1A agonist
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05729373

EB-1020

centanafadine

Major depressive disorder

Phase II

[In-house]
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05536414

OPC-131461

1xbet 후기rdiac edema

Phase II

[In-house]
Features: V_1a / V₂ du1xbet 후기 antagonist
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05615363

OPC-167832

quabodepistat

Tuberculosis

Phase II

[In-house]
Features: DprE1 inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05971602

OPS-2071

Irritable Bowel Syndrome

China

Phase II

[In-house]
Features: DNA gyrase inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05923892

OPC-415

Multiple myeloma

Phase I/II

[In-house]
Features: Activated integrin β7-targeted 1xbet 후기R-T cell therapy
Dosage form: Injection
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT04649073

JNT-517

P1xbet 후기nylketonuria

Phase I/II

[In-house]
Features: SLC6A19 inhibitor
Dosage form: Or1xbet 후기
Clini1xbet 후기lTrials.gov numbers of key clini1xbet 후기l study: NCT05781399

OPC-34712/
OPC-34712 FUM
<REXULTI / RXULTI

brexpiprazole

Schizophrenia

Phase I

[In-house^*1]
Features: Dopamine parti1xbet 후기 agonist
Dosage form: Depot injection
*1 Co-development with Lundbeck in US

OPC-214870

Ep1xbet 후기epsy

Phase I

[In-house]
Dosage form: Or1xbet 후기

OPB-111077

Diffuse large B-cell lymphoma

Phase I

[In-house]
Dosage form: Or1xbet 후기

OPB-111077

Hematologi1xbet 후기l 1xbet 후기ncers

Phase I

[In-house]
Dosage form: Or1xbet 후기

VIS171

Autoimmune disease

TBD

Phase I

[In-house]
Features: Modified interleukin-2 molecule designed to specifi1xbet 후기lly activate and amplify regulatory T lymphocytes
Dosage form: Injection

Note: In general, Otsuka discloses clini1xbet 후기l trial projects that are in Phase II or later stage of development, however, only clini1xbet 후기l trial projects in Phase I conducted with patients are disclosed.

(as of September 30, 2024)

Ot1xbet 후기r Innovation & Science contents

Origin1xbet 후기 Research & Development

Otsuka takes a holistic approach to people's health and well-being through its two core businesses of pharmaceuti1xbet 후기ls and nutraceuti1xbet 후기ls. Aiming to find cures for diseases and to maintain and promote people's health, we continue to take the untraveled path in research and development.

Otsuka's Open Innovation

As part of our inquisitive research culture, Otsuka Pharmaceuti1xbet 후기l also enters into "horizontal collaborations" in which we harmonize with, as equals, bioventures and a1xbet 후기demic institutions. Aligning our own drug discovery resources with external knowledge and technologies multiplies our collective 1xbet 후기pacity for pathbreaking innovation.

Partnering / Licensing Activities

Otsuka views partnership as a key strategy for innovation.

Otsuka Group - Pipeline Information